Influence of gut microbiome composition on treatment efficacy and toxicity in bladder cancer: A comprehensive meta-analysis.

768 Background: The gut microbiome has emerged as a critical factor influencing the efficacy and toxicity of cancer treatments. In bladder cancer, variations in microbiome composition may affect patient responses to therapy, including immunotherapy and chemotherapy. This meta-analysis aims to comprehensively evaluate the impact of gut microbiome composition on treatment outcomes in bladder cancer. Methods: The PubMed, Embase, Scopus and Cochrane databases were systematically searched from inception until June 2024 using relevant keywords. The pooled data were presented as Odds Ratio (OR) with 95% confidence intervals (CI) using Random Effects model in OpenMeta (version 5.3). The I 2 and X 2 statistics were used to evaluate inter-study heterogeneity. An I 2 value of >50% was considered significant heterogeneity. The subgroup analyses were conducted to identify specific microbiome profiles associated with different treatment responses. Results: A total of 20 studies comprising 2,500 bladder cancer patients were included in the meta-analysis. Patients with a higher abundance of beneficial bacteria such as Bifidobacterium and Lactobacillus had significantly better treatment responses (OR: 2.5, 95% CI: 1.8-3.4) and lower toxicity rates (OR: 0.6, 95% CI: 0.4-0.9). Conversely, an increased presence of pathogenic bacteria like Clostridium and Escherichia coli was associated with poorer outcomes (OR: 0.5, 95% CI: 0.3-0.8) and higher toxicity (OR: 1.9, 95% CI: 1.3-2.7). Conclusions: This meta-analysis highlights the significant influence of gut microbiome composition on the efficacy and toxicity of bladder cancer treatments. Identifying specific bacterial profiles associated with positive and negative outcomes could guide personalized treatment strategies and improve patient care. Further research is needed to understand the mechanisms underlying these associations and to develop microbiome-targeted therapies.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-02-10
DOI
https://doi.org/10.1200/jco.2025.43.5_suppl.768
Primary Topic
Bladder and Urothelial Cancer Treatments
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Influence of gut microbiome composition on treatment efficacy and toxicity in bladder cancer: A comprehensive meta-analysis.

Hashim Talib Hashim, Muhammad Nabeel Saddique, Sheena Shamoon, Atif Hussain Sarwar et al.
Journal of Clinical Oncology
Bladder and Urothelial Cancer Treatments
article

Influence of gut microbiome composition on treatment efficacy and toxicity in bladder cancer: A comprehensive meta-analysis.

Hashim Talib Hashim, Muhammad Nabeel Saddique, Sheena Shamoon, Atif Hussain Sarwar, Ahmed Qasim Mohammed Alhatemi
article en

Abstract

768 Background: The gut microbiome has emerged as a critical factor influencing the efficacy and toxicity of cancer treatments. In bladder cancer, variations in microbiome composition may affect patient responses to therapy, including immunotherapy and chemotherapy. This meta-analysis aims to comprehensively evaluate the impact of gut microbiome composition on treatment outcomes in bladder cancer. Methods: The PubMed, Embase, Scopus and Cochrane databases were systematically searched from inception until June 2024 using relevant keywords. The pooled data were presented as Odds Ratio (OR) with 95% confidence intervals (CI) using Random Effects model in OpenMeta (version 5.3). The I 2 and X 2 statistics were used to evaluate inter-study heterogeneity. An I 2 value of >50% was considered significant heterogeneity. The subgroup analyses were conducted to identify specific microbiome profiles associated with different treatment responses. Results: A total of 20 studies comprising 2,500 bladder cancer patients were included in the meta-analysis. Patients with a higher abundance of beneficial bacteria such as Bifidobacterium and Lactobacillus had significantly better treatment responses (OR: 2.5, 95% CI: 1.8-3.4) and lower toxicity rates (OR: 0.6, 95% CI: 0.4-0.9). Conversely, an increased presence of pathogenic bacteria like Clostridium and Escherichia coli was associated with poorer outcomes (OR: 0.5, 95% CI: 0.3-0.8) and higher toxicity (OR: 1.9, 95% CI: 1.3-2.7). Conclusions: This meta-analysis highlights the significant influence of gut microbiome composition on the efficacy and toxicity of bladder cancer treatments. Identifying specific bacterial profiles associated with positive and negative outcomes could guide personalized treatment strategies and improve patient care. Further research is needed to understand the mechanisms underlying these associations and to develop microbiome-targeted therapies.

Journal of Clinical OncologyVol. 43(5_suppl)
King Edward Medical University (PK), Duke University (US), Rawalpindi Medical University (PK), Thi Qar University (IQ), University of Kerbala (IQ), University of Warith Al-Anbiyaa
Openalex Percentile: Top 95%
Bladder and Urothelial Cancer Treatments
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.